

29th January, 2019 – For immediate release

Medcan Australia - Medcan increases its product offering with the addition of 5 new Medicinal Cannabis Products

Medcan Australia (Medcan) is pleased to announce it has increased its Australian product offering with the addition of 5 new Medicinal Cannabis Products. These products have now cleared both customs and quarantine and are ready for dispatch to pharmacies around the country.

Medcan's product range now includes:

- MEDCAN NQ01 - Dried Flower product – 13% THC
- MEDCAN CC01 - Dried Flower product – 21% THC
- MEDCAN FX01 - Cannabis Oil – 20mg/ml THC
- MEDCAN FX02 - Cannabis Oil – 5mg/ml THC, 8mg/ml CBD
- MEDCAN GC01 - Cannabis Capsules – 8mg THC
- MEDCAN GC02 - Cannabis Capsule – 5mg THC, 8mg CBD
-

MEDCAN products are on the TGA website however MEDCAN products are not listed on the (ARTG) Australian Register of Therapeutic Goods and are only available via the Authorised Prescriber Scheme (AP) or the Special Access Scheme (SAS Cat. A or SAS Cat. B)

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia:

Medcan Australia Founder, Craig Cochran said: “Medcan now have a greater range of medicinal cannabis products to meet Australian patient needs. These products are helping to bring the cost down for the patients, while still meeting the highest quality standards”

“Medcan have been actively focused on addressing the 2 main issues raised by both doctors and patients; 1) cost of products are simply too high, 2) lack of continuity of supply and quality of product. We believe our range of products now helps to address both of these issues.”

Craig continued: “Medcan intend to be producing our own locally cultivated and manufactured products by the 2nd half of 2020. However, to meet the current local demand and to help understand local patient needs, we have sourced and imported what we believe are the highest quality medicinal cannabis products which all meet TGO93 standards”.

Background

Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products. The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan Australia are one of only a few companies in Australia to hold the full suite of ODC (Office of Drug Control) Licences, State Licences & DAWR Permit being:

- 1) Cultivation and Production Licence - no. MC013/17

- 2) Manufacture Licence - no. ML015/18
- 3) Research Licence – no. RL18/19
- 4) Import Licence - no. 1821087
- 5) Export Licence - no. 1821088
- 6) DAWR Permit - no. 0002005875
- 7) QLD Health Poison's Licence - no. AG007354718
- 8) QLD Wholesaling Approval – no. C-MC-1289

Medcan Australia will be producing a range of high quality Medicinal Cannabis strains with varying CBD & THC profiles to suit varying medicinal applications, with all of our products manufactured under GMP certification, ensuring consistent medicine for patients.

For further information on Medcan's expansion plans: <https://www.bluemountcapital.com/MCG/>

For Further Information please contact:



Gareth Ball
+61414860512
Po Box 4579, Springfield, QLD, Australia, 4300
gareth@medcanaustralia.com.au
www.medcanaustralia.com.au